TCTAP 2026 Sponsors

GE HealthCare Korea

Logo
GE HealthCare is a global medtech leader committed to advancing precision care through innovative imaging, diagnostics, and digital solutions. With a long heritage in clinical excellence, the company continues to shape the future of patientcentered healthcare.

The Pharmaceutical Diagnostics business plays a vital role in enabling accurate and reliable imaging. Through rigorous science, global manufacturing standards, and close partnership with clinicians, the division support diverse modalities and clinical pathways. Its contrast agents are designed to deliver consistent quality, diagnostic confidence, and meet the demands of complex, real-world practice.

Among its products, Visipaque stands out as a widely trusted contrast medium in cardiovascular interventions. Known for its iso-osmolar profile and strong safety performance, it has a clinical benefit to minimize patient risk while maintaining high diagnostic clarity, for vulnerable populations or high risk procedures.

Satellite Symposium

Evening Symposium

Clinical Value of IOCM in Reducing MARCE in High-Risk Cardiovascular Interventions

Organized by CVRF and Supported by Educational Grant From GE HealthCare Korea

Wednesday, April 29
7:00 PM ~ 8:10 PM * KST (UTC/GMT +9:00)
Room 202, Level 2
Moderator(s): Duk-Woo Park
7:00 PM Openging Remark
7:05 PM Pre-Procedural Planning With CCTA: Current Guidelines and Emerging Evidence
Lecturer: Chul-Hwan Park
7:25 PM Why Contrast Media Matter During Interventions: Mechanistic Insights of IOCM for Safer Clinical Outcome
Lecturer: Si-Hyuck Kang
7:45 PM Translating Mechanism Into Practice: Real-World Evidence and Clinical Experience in PCI and TAVI
Lecturer: In-Ho Yang
8:05 PM Closing Remark